Feliksas Jankevicius
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Feliksas Jankevicius has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Albertas Ulys
National Cancer Institute of Lithuania Vilnius Lithuania
7 shared publications - Alvydas Vezelis
National Cancer Institute, Santariskiu Street 1, Vilnius, LT 08660, Lithuania
4 shared publications - Arnas Bakavicius
Clinic of Gastroenterology, Nephro-Urology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, M. K. Ciurlionio st. 21/27, LT-03101 Vilnius, Lithuania
4 shared publications - Sonata Jarmalaite
Institute of Biosciences, Life Sciences Center, Vilnius University
4 shared publications M. Kincius
3 shared publications- Marija Barisiene
Center of Urology, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
3 shared publications
Latest Publications
- 30 December 2021
- Published by Wiley in The Prostate
- Vol. 82 (4) , 475-482
Urinary microRNAs can predict response to abiraterone acetate in castration resistant prostate cancer: A pilot study
Background: Despite novel agents have been introduced to treat castration resistant prostate cancer (CRPC) during the last decade, up to one‐third of CRPC patients face primary resistance to new generation compounds. Therefore, sensitive molecular tools are urgently needed for reliable treatment selection and response prediction. This study aimed to evaluate urinary miRNAs and blood circulating androgen receptor (AR) transcript level as a tool for noninvasive outcome prediction for CRPC patients undergoing abiraterone acetate (AA) therapy.Methods: Prostate cancer‐specific miR‐148a, ‐365, ‐375, and ‐429 were analyzed in 129 urine samples collected from 100 CRPC patients before and during AA therapy via quantitative reverse transcription PCR. To test the prognostic value, urinary miRNA levels alone, as well as combined with AR level were associated with progression‐free survival (PFS) and overall survival (OS).Results: Level of urinary miR‐375 was the highest in CRPC in comparison to noncancerous controls, as well as in combination with miR‐429 was predictive for short PFS in AA‐treated patients (HR = 2.2, 95% CI: 1.1–4.2, p = 0.023). Especially high prognostic power of all analyzed miRNAs was observed in CRPC cases with high blood AR levels. For PFS prediction a tandem of miR‐429 and high AR reached HR of 5.0 (95% CI: 2.2–11.8, p < 0.001), while for prediction of OS the best combination was demonstrated by miR‐148a and AR with HR of 3.1 (95% CI: 1.4–7.1, p = 0.006).Conclusions: Urinary miRNAs could be used as prognostic biomarkers for CRPC patients to predict response to AA therapy, especially for the cases with high blood AR levels.
- 30 December 2021
- Published by Wiley in The Prostate
- Vol. 82 (4) , 475-482
Urinary microRNAs can predict response to abiraterone acetate in castration resistant prostate cancer: A pilot study
Background: Despite novel agents have been introduced to treat castration resistant prostate cancer (CRPC) during the last decade, up to one‐third of CRPC patients face primary resistance to new generation compounds. Therefore, sensitive molecular tools are urgently needed for reliable treatment selection and response prediction. This study aimed to evaluate urinary miRNAs and blood circulating androgen receptor (AR) transcript level as a tool for noninvasive outcome prediction for CRPC patients undergoing abiraterone acetate (AA) therapy.Methods: Prostate cancer‐specific miR‐148a, ‐365, ‐375, and ‐429 were analyzed in 129 urine samples collected from 100 CRPC patients before and during AA therapy via quantitative reverse transcription PCR. To test the prognostic value, urinary miRNA levels alone, as well as combined with AR level were associated with progression‐free survival (PFS) and overall survival (OS).Results: Level of urinary miR‐375 was the highest in CRPC in comparison to noncancerous controls, as well as in combination with miR‐429 was predictive for short PFS in AA‐treated patients (HR = 2.2, 95% CI: 1.1–4.2, p = 0.023). Especially high prognostic power of all analyzed miRNAs was observed in CRPC cases with high blood AR levels. For PFS prediction a tandem of miR‐429 and high AR reached HR of 5.0 (95% CI: 2.2–11.8, p < 0.001), while for prediction of OS the best combination was demonstrated by miR‐148a and AR with HR of 3.1 (95% CI: 1.4–7.1, p = 0.006).Conclusions: Urinary miRNAs could be used as prognostic biomarkers for CRPC patients to predict response to AA therapy, especially for the cases with high blood AR levels.
- 1 November 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (11) , e3416
Multi-parametric MRI performance using PI-RADS v2 in detecting clinically significant prostate cancer after negative biopsy and persisting suspicion of malignancy
- 1 November 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (11) , e3416
Multi-parametric MRI performance using PI-RADS v2 in detecting clinically significant prostate cancer after negative biopsy and persisting suspicion of malignancy
- 1 May 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (3) , e2435
Urinary 3-gene methylation test for prostate cancer risk assessment
- 1 May 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (3) , e2435
Urinary 3-gene methylation test for prostate cancer risk assessment
- 1 May 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (3) , e2437
Whether p2PSA, %p2PSA and Prostate Health Index improves clinically significant prostate cancer detection in men with PSA range 2-10 ng/ml
- 1 May 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (3) , e2437
Whether p2PSA, %p2PSA and Prostate Health Index improves clinically significant prostate cancer detection in men with PSA range 2-10 ng/ml
- 1 May 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (3) , e2436
The ability of different clinical-pathological criteria’s to detect insignificant prostate cancer after transperineal template mapping biopsies
- 1 May 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (3) , e2436
The ability of different clinical-pathological criteria’s to detect insignificant prostate cancer after transperineal template mapping biopsies
- 1 May 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (3) , e2427-e2428
Diagnostic performance of PCA3 and TMPRSS2:ERG biomarkers in prostate cancer patients urine collected with and without prostate massage
- 1 May 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (3) , e2427-e2428
Diagnostic performance of PCA3 and TMPRSS2:ERG biomarkers in prostate cancer patients urine collected with and without prostate massage
- Open Access
- 14 May 2018
- Published by Vilnius University Press in Acta medica Lituanica
- Vol. 25 (1) , 31-37
Malignant mixed epithelial and stromal tumour of the kidney: a case report and a literature review
Introduction. Mixed epithelial and stromal tumour of the kidney (MEST) is a rare and distinctive neoplasm accounting for 0.2% of all renal cancers. Most of these tumours behave in a benign fashion but 13 cases with malignant transformation have already been reported. We present the first case of an extremely aggressive MEST with rapid recurrence after radical treatment, demonstrating objective response to chemotherapy. Case presentation. A 31-year-old female presented to the hospital complaining of gross hematuria. Computed tomography (CT) revealed an intraparenchymal mass in the left kidney forming a tumour thrombus in the inferior vena cava (IVC). Metastatic disease was ruled out and, under the clinical diagnosis of renal cell carcinoma, left radical nephrectomy with IVC thrombectomy was performed. The histopathological examination confirmed malignant MEST of the kidney. At the follow-up 12 months after surgery, a recurrent tumour in the left paravertebral area and a tumour thrombus in the IVC were detected. A second surgery was recommended and the mass from the paravertebral area was removed, so resection of the IVC with prosthetic replacement was performed. The histopathologic examination confirmed a recurrent malignant MEST. At the follow-up three months after the second surgery disease progression was diagnosed, so chemotherapy with ifosfamide and doxorubicin was initiated. The CT scan performed 14 months after the chemotherapy confirmed a stable process of the disease with no signs of progression. Conclusions. A literature review and our case report confirm the existence of extremely aggressive malignant MEST that shows response to chemotherapy. However, more reports are needed to improve our understanding about the biology of the MEST to develop any recommendations on personalized therapy.
- 14 May 2018
- Published by Vilnius University Press in Acta medica Lituanica
- Vol. 25 (1) , 31-37
Open AccessMalignant mixed epithelial and stromal tumour of the kidney: a case report and a literature review
Introduction. Mixed epithelial and stromal tumour of the kidney (MEST) is a rare and distinctive neoplasm accounting for 0.2% of all renal cancers. Most of these tumours behave in a benign fashion but 13 cases with malignant transformation have already been reported. We present the first case of an extremely aggressive MEST with rapid recurrence after radical treatment, demonstrating objective response to chemotherapy. Case presentation. A 31-year-old female presented to the hospital complaining of gross hematuria. Computed tomography (CT) revealed an intraparenchymal mass in the left kidney forming a tumour thrombus in the inferior vena cava (IVC). Metastatic disease was ruled out and, under the clinical diagnosis of renal cell carcinoma, left radical nephrectomy with IVC thrombectomy was performed. The histopathological examination confirmed malignant MEST of the kidney. At the follow-up 12 months after surgery, a recurrent tumour in the left paravertebral area and a tumour thrombus in the IVC were detected. A second surgery was recommended and the mass from the paravertebral area was removed, so resection of the IVC with prosthetic replacement was performed. The histopathologic examination confirmed a recurrent malignant MEST. At the follow-up three months after the second surgery disease progression was diagnosed, so chemotherapy with ifosfamide and doxorubicin was initiated. The CT scan performed 14 months after the chemotherapy confirmed a stable process of the disease with no signs of progression. Conclusions. A literature review and our case report confirm the existence of extremely aggressive malignant MEST that shows response to chemotherapy. However, more reports are needed to improve our understanding about the biology of the MEST to develop any recommendations on personalized therapy.
- 1 May 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (5) , e2171
Promoter hypermethylation of tumor suppressor genes in renal cell carcinoma
- 1 May 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (5) , e2171
Promoter hypermethylation of tumor suppressor genes in renal cell carcinoma